Dr. Reddy's Laboratories Limited

500124

INE089A01031

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 03:30:49 15/06/2026 pm IST			5-day change	1st Jan Change
1,279.25 ^INR	+0.42%		+0.27%	+0.65%

04:26pm	Global drugmakers rush to boost US presence as tariff threat looms	RE
09:15am	Indian shares join global rally on Gulf peace deal, oil slides	RE

Dr. Reddy's Laboratories Limited Approves Elevation of Sandeep Khandelwal, Global Generics India Head as Senior Management Personnel, Effective May 12, 2026

Published on 05/12/2026 at 05:08 pm IST

S&P Capital IQ

DR. REDDY'S LABORATORIES LIMITED

+0.42%

Dr. Reddy's Laboratories Limited approved elevation of Mr. Sandeep Khandelwal, Global Generics India Head as a Senior Management Personnel of the Company and induction as a member of the Management Council, effective May 12, 2026. The Board of Directors of the Company had considered and approved the change at its meeting held on May 12, 2026.

Latest news about Dr. Reddy's Laboratories Limited

04:26pm	Global drugmakers rush to boost US presence as tariff threat looms	RE
09:15am	Indian shares join global rally on Gulf peace deal, oil slides	RE
08:05am	Indian shares set to join global rally on Gulf peace deal, oil slides	RE
13/06	Dr. Reddy?s Laboratories Announces First-To-Market Launch Of Bosutinib Tablets 400Mg, A Generic Equivalent Of Bosulif, In The United States	CI
08/06	Asian Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
05/06	Asian Equities Traded in the US as American Depositary Receipts Fall in Friday Trading	MT
01/06	Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Monday Trading	MT
01/06	Caring Brands Inks Expanded Five-Year Licensing Deal With SanPellegrino Cosmetics	MT
29/05	Asian Equities Traded in the US as American Depositary Receipts Decline in Friday Trading; Up for Week	MT
29/05	Inadvertently published alert on NYSE tagged to multiple companies withdrawn	RE
27/05	Asian Equities Traded in US as ADRs Fall in Wednesday Trading	MT
26/05	Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading	MT
22/05	India's Sun Pharma posts profit beat on specialty drug demand, shares slide on cost pressures	RE
20/05	Dr Reddy's launches oral semaglutide biosimilar Obeda in India	RE
19/05	R-Pharm Group of Companies and Dr. Reddy?S Laboratories Ltd. Signs Agreement to Localize Production of Toripalimab for Tumor Therapy	CI

Chart Dr. Reddy's Laboratories Limited

Duration

Period

500124: Dynamic Chart

Company Profile

Dr. Reddyâ€™s Laboratories Limited is an India-based pharmaceutical company. Its products and services are spread across its core businesses of active pharmaceutical ingredients (APIs), generics, branded generics, biosimilars and over-the-counter (OTC) pharmaceutical products. It works in the areas of gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its segments consist of Global Generics; Pharmaceutical Services and Active Ingredients (PSAI), and Others. The Global Generics segment consists of the Company's business of manufacturing and marketing prescription and over-the-counter finished pharmaceutical products ready for consumption by the patient, marketed under a brand name (branded formulations) or as generic finished dosages with therapeutic equivalence to branded formulations (generics). The Pharmaceutical Services and Active Ingredients segment consists of the Company's business of manufacturing and marketing APIs and intermediates.

Employees

27,527

Sector

Pharmaceuticals

Calendar

10/07 - Ex-dividend date - 8 INR

More about the company